Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
Portfolio Pulse from
Jaguar Health has announced the dosing of the first patient in a trial for Crofelemer, a drug for Short Bowel Syndrome with Intestinal Failure. The trial is taking place in Abu Dhabi, and the drug has received Orphan Drug Designation from the FDA and EMA. Proof-of-concept data may be available by H1 2025, potentially leading to early patient access in Europe.

February 03, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health's Crofelemer has begun trials for treating SBS-IF, with potential proof-of-concept data by H1 2025. The drug has Orphan Drug Designation, which could lead to early access in Europe.
The initiation of the trial and the Orphan Drug Designation are positive developments for Jaguar Health, potentially leading to early market access in Europe. This could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100